|
|
| Research article summary (published 13 Nov 2009): |
Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences.
Full Abstract
Interleukin-6 (IL-6) may play a role in the pathogenesis of hepatocellular carcinoma (HCC). Recently, it was reported in mouse models that estrogen-mediated inhibition of IL-6 production explains the gender disparity in HCC. We conducted a retrospective cohort study to examine whether this hypothesis is applicable to human HCC. We enrolled 330 patients with chronic hepatitis C whose serum samples were collected between January 1994 and December 2002. Serum IL-6 concentrations were measured and patients were divided into three groups according to IL-6 levels: low, middle, and high. We evaluated the association between serum IL-6 levels and the risk of subsequent HCC development, including subgroup analysis on each gender. During the follow-up period (mean 9.0 yr), HCC developed in 126 patients. The incidence rates differed significantly among the three groups (p = 0.015), increasing in accordance with serum IL-6 levels. However, unexpectedly, this tendency was significant only in female patients. In a multivariate analysis, higher serum IL-6 level was an independent risk factor for HCC development in female patients, with a hazard ratio of 1.61. Although female patients showed a weak negative correlation between serum IL-6 levels and estradiol levels, the lower risk of HCC in female patients cannot be fully explained by estrogen-mediated inhibition of IL-6 production. In conclusion, higher serum IL-6 level was an independent risk factor for HCC development in female but not male chronic hepatitis C patients. Measurement of serum IL-6 levels may provide useful information for predicting future HCC development in female chronic hepatitis C patients.
Author information
Author/s: Nakagawa, Hayato (H); Maeda, Shin (S); Yoshida, Haruhiko (H); Tateishi, Ryosuke (R); Masuzaki, Ryota (R); Ohki, Takamasa (T); Hayakawa, Yoku (Y); Kinoshita, Hiroto (H); Yamakado, Minoru (M); Kato, Naoya (N); Shiina, Shuichiro (S); Omata, Masao (M);
Affiliation: Department of Gastroenterology, University of Tokyo, Tokyo 113-8655, Japan. n-hayato(-atsign-)yf7.so-net.ne.jp
Journal and publication information
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Journal: International journal of cancer. Journal international du cancer (Int J Cancer), published in United States. (Language: eng)
Reference: 2009-Nov; vol 125 (issue 10) : pp 2264-9
Dates: Created 2009/09/28; Completed 2009/11/05;
PMID: 19585572, status: MEDLINE (last retrieval date: 11/5/2009, IMS Date: )
Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.
External Links for this article
(including full text providers, if available):
Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.
This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.
MeSH headings (categories)
This article was linked to the MESH Headings shown below.
Related articles
These are the highest related articles currently in the database:
- Elevated levels of circulating cell-free DNA in the blood of patients with hepatitis C virus-associated hepatocellular carcinoma.
30 Oct 2006 - Plasma selenium levels and risk of hepatocellular carcinoma among men with chronic hepatitis virus infection.
13 Aug 1999 - Increase of serum beta2-microglobulin in patients affected by HCV correlated hepatocellular carcinoma.
30 Jul 2000 - Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence is not a predictive factor for response to interferon-alpha therapy and development of hepatocellular carcinoma.
30 Jan 2000 - Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients.
30 Oct 2000 - The predictive ability of serum alpha-fetoprotein for hepatocellular carcinoma is linked with the characteristics of the target population at surveillance.
13 Jun 2007 - Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis.
30 May 2001 - Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma.
22 Oct 2007 - HCV RNA levels in hepatocellular carcinomas and adjacent non-tumorous livers.
29 Sep 2000 - [Prospect of the study on the relation between hepatitis C virus and hepatocellular carcinoma]
29 Sep 1997
Related Article Map
Legend:
- FREE Full text Article.
- Abstract only.
- Title only. More help.
See a large map of 100+ related articles.